title: Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies.
abstract: Soluble CD27 (sCD27) reportedly is a sensitive and specific marker for leptomeningeal involvement (LI) of CD27-expressing lymphoproliferations such as B-cell non-Hodgkin's lymphoma (B-NHL) or chronic B-lymphocytic leukemia (B-CLL). Because morphological analysis of cerebrospinal fluid (CSF) in patients suspected of LI is false negative in one-third of patients, a diagnostic marker for LI by B-NHL or B-CLL would be very valuable. sCD27 was determined in the first CSF sample from each of 102 unselected patients submitted for (immuno)morphologic detection of malignant cells. The patients were considered to have LI if either (immuno)morphologic analyses showed tumor cells or if neuroradiological evaluation showed typical abnormalities consistent with LI. Patients were suspected of having LI if CSF samples revealed atypical lymphocytes and/or if clinical symptoms and signs suggestive of LI were present, but clinical follow-up was shorter than 3 months because of deterioration of the patient. LI was considered absent if (immuno)morphologic analyses of CSF samples were negative without evidence for LI during 3 months of clinical follow-up. In patients with chronic lymphoproliferative disorders [mainly B-non-Hodgkin's lymphoma (NHL)], sCD27 concentrations were significantly higher in the CSF samples of 16 patients with confirmed or suspected LI than in those of 46 patients without LI. However, sCD27 was also increased in a variety of other predominantly inflammatory neurological disorders including herpes simplex and zoster infections. The positive predictive value of sCD27 determination for LI was only 54%, but the negative predictive value was 92%. Normal sCD27 concentrations in CSF samples of patients with chronic lymphoproliferation makes LI unlikely, but the determination of CSF sCD27 is not sufficiently specific to serve as a reliable tumor marker.
authors.affiliation: Department of Neuro-Oncology, University Hospital and Daniel den Hoed Cancer Center, P.O. Box 5201, 3008 AE Rotterdam, Netherlands. bent@neuh.azr.nl
authors.forename: M J
authors.initials: MJ
authors.lastname: van den Bent
authors.forename: C H J
authors.initials: CH
authors.lastname: Lamers
authors.forename: M B
authors.initials: MB
authors.lastname: van 't Veer
authors.forename: P A E
authors.initials: PA
authors.lastname: Sillevis Smitt
authors.forename: R L H
authors.initials: RL
authors.lastname: Bolhuis
authors.forename: J W
authors.initials: JW
authors.lastname: Gratama
mesh_terms: D014408:Biomarkers, Tumor / Q000134:cerebrospinal fluid; D003951:Diagnostic Errors / Q000517:prevention & control; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D016393:Lymphoma, B-Cell / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D011237:Predictive Value of Tests; D012995:Solubility; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000134:cerebrospinal fluid*
chemical_list: D014408:Biomarkers, Tumor; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7